NeuPath Health (NPTH) investor relations material

Executive summary

• Achieved over 26% revenue growth in Q3 2025, reaching $22.1 million, driven by higher patient volumes and optimized clinic operations.

• Adjusted EBITDA increased by 98% year-over-year to $1.5 million, marking the 27th consecutive quarter of positive Adjusted EBITDA.

• Focused on regulated healthcare facilities providing chronic pain, sports injury, and concussion treatments in Ontario and Alberta.

• Expansion into Alberta with HealthPoint acquisition and rapid growth at the Red Deer site.

• Strong growth attributed to increased demand for ArthrosamidⓇ and operational improvements.

Financial highlights

• Q3 revenue up 26% year-over-year to $22.1 million; year-to-date revenue up 21% to $65 million from $53 million.

• Clinic revenue was $20.8 million for Q3 2025, up from $16.3 million in Q3 2024; non-clinic revenue was $1.3 million.

• Adjusted EBITDA for the trailing 12 months nearly $6 million; Q3 2025 margin was approximately 6.6%.

• Cash balance at quarter-end was $4.6 million; net debt reduced to $1.7 million.

• Gross margin improved to 19.1% for Q3 2025 from 18.3% in Q3 2024.

Outlook and guidance

• Expecting continued high single to low double-digit organic growth over the next 12 months, with ongoing operational improvements.

• Anticipates executing several acquisitions in the coming year, with a robust pipeline of over a dozen opportunities.

• Ongoing focus on increasing physician hours and adding new services to drive patient volume.